Personalized Cancer Vaccine Shows Promise In Major Trial

Pharmaceutical companies Merck and Moderna reported that an experimental personalized mRNA vaccine, given alongside the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. The Phase 3 trial included 1,137 patients with Stage IIB-IV melanoma whose tumors had been surgically removed. The findings could bring the drugmakers ...

Read it at Daily Wire ↗

← Front page